Kodiak Sciences Inc. (NASDAQ: KOD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 62.58M | Perf Week | 9.11% |
| Market Cap | 2.84B | Forward P/E | - | EPS next Y | -3.23 | Insider Trans | -0.16% | Shs Float | 57.89M | Perf Month | 13.20% |
| Enterprise Value | 2.83B | PEG | 0.77 | EPS next Q | - | Inst Own | - | Short Float | 17.99% | Perf Quarter | 3.87% |
| Income | -233.38M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 14.04 | Perf Half Y | 115.94% |
| Sales | 0.00 | P/B | 25.04 | EPS next Y | 13.01% | ROA | -75.38% | Short Interest | 10.42M | Perf YTD | 62.27% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -253.85% | 52W High | 46.04 -5.16% | Perf Year | 452.62% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -87.69% | 52W Low | 7.40 489.99% | Perf 3Y | 1335.76% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.92% 6.79% | Perf 5Y | 170.54% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -25.97% | Oper. Margin | 0.00% | ATR (14) | 2.75 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.54 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 62.82 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.54 | EPS Q/Q | -11.90% | SMA20 | 7.81% | Beta | 1.96 | Target Price | 63.75 |
| Payout | 0.00% | Debt/Eq | 1.39 | Sales Q/Q | - | SMA50 | 18.63% | Rel Volume | 0.66 | Prev Close | 45.37 |
| Employees | 124 | LT Debt/Eq | 0.94 | Earnings | Aug 12 | SMA200 | 46.00% | Avg Volume | 718.82K | Price | 43.66 |
| IPO Date | Oct 04, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.62% - | Net Debt/EBITDA | 0.07 | Volume | 471,900 | Change | -3.77% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-11-26 | Upgrade | Chardan Capital | Neutral → Buy | $18 → $61 |
| Mar-27-26 | Reiterated | HC Wainwright & Co. | Buy | $38 → $58 |
| Mar-27-26 | Reiterated | UBS | Buy | $50 → $80 |
| Mar-26-26 | Reiterated | Jefferies | Buy | $39 → $56 |
| Jan-22-26 | Reiterated | HC Wainwright & Co. | Buy | $38 |
| Jan-07-26 | Reiterated | UBS | Neutral | $50 |
| Nov-11-25 | Upgrade | HC Wainwright & Co. | Neutral → Buy | |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight | |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight | $17 |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 27 | 26 | — | — | — | — | — | — | |
| Gross Profit | 0 | -27 | -26 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 52 | 34 | 71 | — | — | — | — | — | — | |
| Research and Development | 182 | 126 | 206 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -26 | — | — | — | — | — | — | |
| Operating Income | -234 | -187 | -277 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 11 | 17 | — | — | — | — | — | — | |
| Net Income Before Taxes | -230 | -176 | -260 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -230 | -176 | -260 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -230 | -176 | -260 | — | — | — | — | — | — | |
| Net Income | -230 | -176 | -260 | — | — | — | — | — | — | |
| EPS (Recurring) | -4.32 | -3.35 | -4.97 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.32 | -3.35 | -4.97 | — | — | — | — | — | — | |
| EPS (Diluted) | -4.32 | -3.35 | -4.97 | — | — | — | — | — | — | |
| EBITDA | -204 | -150 | -235 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 53 | 53 | 52 | — | — | — | — | — | — | |
| Market Capitalization | 1,482 | 527 | 158 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | Chief Financial Officer | Jun 04 '26 | Option Exercise | 1.04 | 30,000 | 31,200 | 241,930 | Jun 05 |
| BORGESON JOHN A. | Chief Financial Officer | Jun 04 '26 | Sale | 34.10 | 30,000 | 1,023,009 | 211,930 | Jun 05 |
| BORGESON JOHN A. | Chief Financial Officer | Apr 15 '26 | Option Exercise | 1.04 | 28,614 | 29,759 | 211,930 | Apr 16 |
| BORGESON JOHN A. | Chief Financial Officer | Apr 02 '26 | Sale | 39.92 | 30,000 | 1,197,488 | 183,316 | Apr 02 |
| BORGESON JOHN A. | Chief Financial Officer | Apr 02 '26 | Option Exercise | 1.04 | 30,000 | 31,200 | 213,316 | Apr 02 |
| PERLROTH VICTOR | Chairman and CEO | Mar 25 '26 | Option Exercise | 1.04 | 300,000 | 312,000 | 2,395,538 | Mar 27 |
| BAKER BROS. ADVISORS LP | director, 10 percent owner: | Dec 18 '25 | Buy | 23.00 | 2,608,696 | 60,000,008 | 18,358,772 | Dec 19 |
| BORGESON JOHN A. | See Remarks | Jun 17 '25 | Sale | 3.65 | 723 | 2,640 | 183,316 | Jun 17 |
| BORGESON JOHN A. | See Remarks | Jun 15 '25 | Option Exercise | 0.00 | 1,875 | 0 | 184,039 | Jun 17 |
| BORGESON JOHN A. | See Remarks | Jun 17 '24 | Sale | 2.75 | 2,874 | 7,904 | 182,164 | Jun 18 |
| BORGESON JOHN A. | See Remarks | Jun 15 '24 | Option Exercise | 0.00 | 10,988 | 0 | 185,038 | Jun 18 |
| BORGESON JOHN A. | See Remarks | Jun 12 '24 | Sale | 2.92 | 1,558 | 4,549 | 179,544 | Jun 13 |
| BORGESON JOHN A. | See Remarks | Jun 11 '24 | Option Exercise | 0.00 | 3,025 | 0 | 181,102 | Jun 13 |
| EHRLICH JASON | See Remarks | Jun 16 '23 | Sale | 9.23 | 2,258 | 20,841 | 61,924 | Jun 16 |
| BORGESON JOHN A. | See Remarks | Jun 16 '23 | Sale | 9.23 | 2,749 | 25,373 | 178,077 | Jun 16 |